Clinical trial
Risk Adapted Beacopp Regimen for Standard and High Risk Hodgkin Lymphoma
NCT00305149 · Rambam Health Care Campus, Other · Completed
Key facts
| NCT number | NCT00305149 |
|---|---|
| Title | Risk Adapted Beacopp Regimen for Standard and High Risk Hodgkin Lymphoma |
| Official title | Use of Risk Factors for Initiation Therapy With Beacopp or Escalated Beacopp and Interim Evaluation and Modification of Therapy Based on Scintigraphy Results. |
| Lead sponsor | Rambam Health Care Campus, Other |
| Status | Completed |
| Study type | Interventional |
| Conditions | Classical Hodgkin Lymphoma, Nodular Sclerosis, Mixed Cellularity, Lymphocyte Depletion, Lymphocyte Rich |
| Intervention type | Procedure |
| Interventions | interim therapy scintigraphy study gallium scan or PET/CT, "interim gallium or PET/CT" |
| Enrollment | 130 |
| Start date | Jul 1, 1999 |
| Completion | Dec 1, 2005 |
| First posted | Mar 21, 2006 |
| Last update posted | Mar 21, 2006 |
| Countries | Israel |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: